Larson Financial Group LLC Sells 564 Shares of Pfizer Inc. (NYSE:PFE)

Larson Financial Group LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 4.5% during the second quarter, HoldingsChannel reports. The firm owned 12,010 shares of the biopharmaceutical company’s stock after selling 564 shares during the period. Larson Financial Group LLC’s holdings in Pfizer were worth $470,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. OLD Mission Capital LLC bought a new position in Pfizer during the third quarter worth about $291,000. Lehman & Derafelo Financial Resources LLC lifted its stake in shares of Pfizer by 3.6% during the 1st quarter. Lehman & Derafelo Financial Resources LLC now owns 212,511 shares of the biopharmaceutical company’s stock valued at $7,699,000 after buying an additional 7,354 shares in the last quarter. Ironwood Wealth Management LLC. lifted its stake in shares of Pfizer by 1.6% during the 1st quarter. Ironwood Wealth Management LLC. now owns 35,385 shares of the biopharmaceutical company’s stock valued at $1,282,000 after buying an additional 550 shares in the last quarter. Petix & Botte Co bought a new position in Pfizer in the 1st quarter worth approximately $187,000. Finally, Los Angeles Capital Management LLC grew its stake in Pfizer by 14.0% in the 1st quarter. Los Angeles Capital Management LLC now owns 719,120 shares of the biopharmaceutical company’s stock valued at $26,054,000 after buying an additional 88,403 shares in the last quarter. Institutional investors and hedge funds own 64.93% of the company’s stock.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total value of $107,150.00. Following the transaction, the senior vice president now owns 11,430 shares in the company, valued at $489,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jennifer B. Damico sold 1,661 shares of the firm’s stock in a transaction dated Friday, August 13th. The stock was sold at an average price of $48.30, for a total value of $80,226.30. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Several brokerages have recently weighed in on PFE. Mizuho lifted their price target on Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Friday, July 30th. Royal Bank of Canada set a $44.00 price target on Pfizer in a research report on Thursday, July 29th. JPMorgan Chase & Co. raised their price objective on shares of Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a research report on Monday. Truist began coverage on shares of Pfizer in a report on Tuesday, July 27th. They set a “buy” rating and a $43.00 target price on the stock. Finally, Morgan Stanley boosted their price target on shares of Pfizer from $42.00 to $45.00 and gave the company an “equal weight” rating in a research report on Thursday, July 29th. Eleven investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $42.77.

NYSE:PFE traded up $0.26 during mid-day trading on Wednesday, reaching $44.97. The stock had a trading volume of 436,963 shares, compared to its average volume of 30,836,189. Pfizer Inc. has a one year low of $33.36 and a one year high of $51.86. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 1.37. The firm has a 50 day moving average price of $44.74 and a two-hundred day moving average price of $40.35. The stock has a market capitalization of $252.13 billion, a P/E ratio of 19.36, a P/E/G ratio of 1.58 and a beta of 0.74.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.10. The company had revenue of $18.98 billion during the quarter, compared to analysts’ expectations of $17.54 billion. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. During the same quarter in the prior year, the company earned $0.78 EPS. Research analysts forecast that Pfizer Inc. will post 4.12 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date was Thursday, July 29th. Pfizer’s dividend payout ratio (DPR) is presently 70.27%.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More: How does the Federal Reserve determine interest rates?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.